Polymorphisms in XPD, XPC and the risk of death in patients with urinary bladder neoplasms

Acta Oncologica

Volumn 46, Issue 1, 2007, Pages 31-41

  Sanyal, Somali ^a,d   De Verdier, Petra J ^a   Steineck, Gunnar ^a,b   Larsson, Per ^a   Onelöv, Erik ^a   Hemminki, Kari ^a,c   Kumar, Rajiv ^a,c  

^a KAROLINSKA INSTITUTE   (Sweden)

^b UNIVERSITY OF GOTHENBURG   (Sweden)

^c GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^d KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; ALLELE; ARTICLE; BLADDER TUMOR; CANCER GROWTH; CANCER RADIOTHERAPY; CANCER RISK; CONTROLLED STUDY; DNA POLYMORPHISM; DNA REPAIR; DRUG INSTILLATION; FEMALE; FOLLOW UP; HETEROZYGOTE; HUMAN; MALE; PRIORITY JOURNAL; REGULATOR GENE; TREATMENT OUTCOME;

AGED; DISEASE PROGRESSION; DNA-BINDING PROTEINS; FEMALE; HUMANS; MALE; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; POLYMORPHISM, GENETIC; URINARY BLADDER NEOPLASMS; XERODERMA PIGMENTOSUM GROUP D PROTEIN;

EID: 33847035198     PISSN: 0284186X     EISSN: 1651226X     Source Type: Journal    
DOI: 10.1080/02841860600812693     Document Type: Article

References (39)

1. Friedberg EC. DNA damage and repair. Nature 2003;421:436-40.
2. Mohrenweiser HW, Xi T, Vazquez-Matias J, Jones IM. Identification of 127 amino acid substitution variants in screening 37 DNA repair genes in humans. Cancer Epidemiol Biomarkers Prev 2002;11:1054-64.
3. Niessen RC, Sijmons RH, Berends MJ, Ou J, Hofstra RM, Kleibeuker JH. Hereditary non-polyposis colorectal cancer: Identification of mutation carriers and assessing pathogenicity of mutations. Scand J Gastroenterol Suppl 2004:70-7.
4. Benhamou S, Sarasin A. Variability in nucleotide excision repair and cancer risk: A review. Mutat Res 2000;462:149-58.
5. Gu J, Zhao H, Dinney CP, Zhu Y, Leibovici D, Bermejo CE, et al. Nucleotide excision repair gene polymorphisms and recurrence after treatment for superficial bladder cancer. Clin Cancer Res 2005;11:1408-15.
6. Catto JW, Xinarianos G, Burton JL, Meuth M, Hamdy FC. Differential expression of hMLH1 and hMSH2 is related to bladder cancer grade, stage and prognosis but not microsatellite instability. Int J Cancer 2003;105:484-90.
7. Bosken CH, Wei Q, Amos CI, Spitz MR. An analysis of DNA repair as a determinant of survival in patients with non-small-cell lung cancer. J Natl Cancer Inst 2002;94:1091-9.
8. Kim WJ, Quan C. Genetic and epigenetic aspects of bladder cancer. J Cell Biochem 2005;95:24-33.
9. Sanyal S, Festa F, Sakano S, Zhang Z, Steineck G, Norming U, et al. Polymorphisms in DNA repair and metabolic genes in bladder cancer. Carcinogenesis 2004;25:729-34.
10. Ryk C, Berggren P, Kumar R, Hemminki K, Larsson P, Steineck G, et al. Influence of GSTM1, GSTT1, GSTP1 and NAT2 genotypes on the p53 mutational spectrum in bladder tumours. Int J Cancer 2005;113:761-8.
11. Sobin LH, Fleming ID. TNM Classification of Malignant Tumors, fifth edition (1997). Union Internationale Contre le Cancer and the American Joint Committee on Cancer. Cancer 1997;80:1803-4.
12. Mostofi FK DC, Sesterhnn IA. Histological typing of urinary bladder tumors. WHO: 1999.
13. Hall RR, Prout GR. Staging of bladder cancer: Is the tumor, node, metastasis system adequate? Semin Oncol 1990;17:517-23.
14. Bergkvist A, Ljungqvist A, Moberger G. Classification of bladder tumours based on the cellular pattern. Preliminary report of a clinical-pathological study of 300 cases with a minimum follow-up of eight years. Acta Chir Scand 1965;130:371-8.
15. Larsson P, Wijkstrom H, Thorstenson A, Adolfsson J, Norming U, Wiklund P, et al. A population-based study of 538 patients with newly detected urinary bladder neoplasms followed during 5 years. Scand J Urol Nephrol 2003;37:195-201.
16. Kumar R, Hoglund L, Zhao C, Forsti A, Snellman E, Hemminki K. Single nucleotide polymorphisms in the XPG gene: Determination of role in DNA repair and breast cancer risk. Int J Cancer 2003;103:671-5.
17. Bernstein C, Bernstein H, Payne CM, Garewal H. DNA repair/pro-apoptotic dual-role proteins in five major DNA repair pathways: Fail-safe protection against carcinogenesis. Mutat Res 2002;511:145-78.
18. Benhamou S, Sarasin A. ERCC2/XPD gene polymorphisms and cancer risk. Mutagenesis 2002;17:463-9.
19. Qiao Y, Spitz MR, Shen H, Guo Z, Shete S, Hedayati M, et al. Modulation of repair of ultraviolet damage in the host-cell reactivation assay by polymorphic XPC and XPD/ERCC2 genotypes. Carcinogenesis 2002;23:295-9.
20. Vodicka P, Kumar R, Stetina R, Sanyal S, Soucek P, Haufroid V, et al. Genetic polymorphisms in DNA repair genes and possible links with DNA repair rates, chromosomal aberrations and single-strand breaks in DNA. Carcinogenesis 2004;25:757-63.
21. Angelini S, Kumar R, Carbone F, Maffei F, Forti GC, Violante FS, et al. Micronuclei in humans induced by exposure to low level of ionizing radiation: influence of polymorphisms in DNA repair genes. Mutat Res 2005;570:105-17.
22. Seker H, Butkiewicz D, Bowman ED, Rusin M, Hedayati M, Grossman L, et al. Functional significance of XPD polymorphic variants: Attenuated apoptosis in human lymphoblastoid cells with the XPD 312 Asp/Asp genotype. Cancer Res 2001;61:7430-4.
23. Butkiewicz D, Rusin M, Enewold L, Shields PG, Chorazy M, Harris CC. Genetic polymorphisms in DNA repair genes and risk of lung cancer. Carcinogenesis 2001;22:593-7.
24. Dybdahl M, Vogel U, Frentz G, Wallin H, Nexo BA. Polymorphisms in the DNA repair gene XPD: Correlations with risk and age at onset of basal cell carcinoma. Cancer Epidemiol Biomarkers Prev 1999;8:77-81.
25. Vogel U, Overvad K, Wallin H, Tjonneland A, Nexo BA, Raaschou-Nielsen O. Combinations of polymorphisms in XPD, XPC and XPA in relation to risk of lung cancer. Cancer Lett 2005;222:67-74.
26. Stout GJ, Oosten MV, Acherrat FZ, Wit JD, Vermeij WP, Mullenders LH, et al. Selective DNA damage responses in murine Xpa(-/-), Xpc(-/-) and Csb(-/-) keratinocyte cultures. DNA Repair (Amst) 2005.
27. Forsti A, Angelini S, Festa F, Sanyal S, Zhang Z, Grzybowska E, et al. Single nucleotide polymorphisms in breast cancer. Oncol Rep 2004;11:917-22.
28. Duckett DR, Bronstein SM, Taya Y, Modrich P. hMutSalpha- and hMutLalpha-dependent phosphorylation of p53 in response to DNA methylator damage. Proc Natl Acad Sci USA 1999;96:12384-8.
29. Thykjaer T, Christensen M, Clark AB, Hansen LR, Kunkel TA, Orntoft TF. Functional analysis of the mismatch repair system in bladder cancer. Br J Cancer 2001;85:568-75.
30. Mohrenweiser HW, Wilson DM, 3rd, Jones IM. Challenges and complexities in estimating both the functional impact and the disease risk associated with the extensive genetic variation in human DNA repair genes. Mutat Res 2003;526:93-125.
31. Stern MC, Umbach DM, Lunn RM, Taylor JA. DNA repair gene XRCC3 codon 241 polymorphism, its interaction with smoking and XRCC1 polymorphisms, and bladder cancer risk. Cancer Epidemiol Biomarkers Prev 2002;11:939-43.
32. Gurubhagavatula S, Liu G, Park S, Zhou W, Su L, Wain JC, et al. XPD and XRCC1 genetic polymorphisms are prognostic factors in advanced non-small-cell lung cancer patients treated with platinum chemotherapy. J Clin Oncol 2004;22:2594-601.
33. Yeh CC, Sung FC, Tang R, Chang-Chieh CR, Hsieh LL. Polymorphisms of the XRCC1, XRCC3, & XPD genes, and colorectal cancer risk: A case-control study in Taiwan. BMC Cancer 2005;5:12.
34. Duell EJ, Wiencke JK, Cheng TJ, Varkonyi A, Zuo ZF, Ashok TD, et al. Polymorphisms in the DNA repair genes XRCC1 and ERCC2 and biomarkers of DNA damage in human blood mononuclear cells. Carcinogenesis 2000;21:965-71.
35. Hu JJ, Smith TR, Miller MS, Mohrenweiser HW, Golden A, Case LD. Amino acid substitution variants of APE1 and XRCC1 genes associated with ionizing radiation sensitivity. Carcinogenesis 2001;22:917-22.
36. Chang-Claude J, Popanda O, Tan XL, Kropp S, Helmbold I, von Fournier D, et al. Association between polymorphisms in the DNA repair genes, XRCC1, APE1, and XPD and acute side effects of radiotherapy in breast cancer patients. Clin Cancer Res 2005;11:4802-9.
37. Sak SC, Harnden P, Johnston CF, Paul AB, Kiltie AE. APE1 and XRCC1 protein expression levels predict cancer-specific survival following radical radiotherapy in bladder cancer. Clin Cancer Res 2005;11:6205-11.
38. Weiss JM, Goode EL, Ladiges WC, Ulrich CM. Polymorphic variation in hOGG1 and risk of cancer: A review of the functional and epidemiologic literature. Mol Carcinog 2005;42:127-41.
39. Johne A, Roots I, Brockmoller J. A single nucleotide polymorphism in the human H-ras proto-oncogene determines the risk of urinary bladder cancer. Cancer Epidemiol Biomarkers Prev 2003;12:68-70.